Asset profile
eDSP · Quince Therapeutics, Inc. (QNCX)
- Indication
- Ataxia-Telangiectasia (A-T)
- Also known as
- encapsulated dexamethasone sodium phosphate, EryDex
Company
QNCXQuince Therapeutics, Inc.
QNCXQuince Therapeutics, Inc.Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automate…
On the calendar
Nothing scheduled in this window.
Timeline
Newest first.
Registered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT02770807 | Phase 3 | Completed | May 13, 2021 | 176 | 4 of 22 sites in the United States |
| NCT06193200 | Phase 3 | Completed | Dec 17, 2025 | 105 | 4 of 19 sites in the United States |
| NCT06664853 | Phase 3 | Terminated | Jan 30, 2026 | 101 | 5 of 21 sites in the United States |
| NCT03563053 | Phase 3 | Terminated | Sep 2, 2022 | 104 | 4 of 17 sites in the United States |
More from Quince Therapeutics, Inc.
Other drugs and candidates from the same company tracked in this sector.